Shenzhen Hepalink Pharmaceutical Co Ltd (002399) — Strategic Asset Allocation Index
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Strategic Asset Allocation Index of 21.0% as of September 2023. Strategic assets (PP&E of CN¥2.62 Billion plus long-term investments of CN¥-) total CN¥2.62 Billion, measured against net assets of CN¥12.50 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 002399 net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Shenzhen Hepalink Pharmaceutical Co Ltd Strategic Asset Allocation Index (2007–2021)
This chart shows how Shenzhen Hepalink Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 15 annual periods from 2007 to 2021. As of September 2023, the index stands at 21.0%, representing strategic assets of CN¥2.62 Billion against net assets of CN¥12.50 Billion CNY. For live market cap and overall valuation, see market cap of Shenzhen Hepalink Pharmaceutical Co Ltd.
Annual Strategic Asset Allocation Index for Shenzhen Hepalink Pharmaceutical Co Ltd (2007–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Shenzhen Hepalink Pharmaceutical Co Ltd from 2007 to 2021, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Shenzhen Hepalink Pharmaceutical Co Ltd (002399) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 22.0% | CN¥2.54 Billion | CN¥2.54 Billion | CN¥- | CN¥11.52 Billion | ▲ +0.0 pp |
| 2020 | 22.0% | CN¥2.57 Billion | CN¥2.57 Billion | CN¥- | CN¥11.69 Billion | ▼ -12.5 pp |
| 2019 | 34.5% | CN¥2.58 Billion | CN¥2.58 Billion | CN¥- | CN¥7.47 Billion | ▼ -4.6 pp |
| 2018 | 39.1% | CN¥2.44 Billion | CN¥2.44 Billion | CN¥- | CN¥6.24 Billion | ▲ +14.6 pp |
| 2017 | 24.5% | CN¥1.88 Billion | CN¥1.88 Billion | CN¥- | CN¥7.69 Billion | ▲ +9.4 pp |
| 2016 | 15.1% | CN¥1.22 Billion | CN¥1.22 Billion | CN¥- | CN¥8.09 Billion | ▲ +2.6 pp |
| 2015 | 12.5% | CN¥1.10 Billion | CN¥1.10 Billion | CN¥- | CN¥8.79 Billion | ▲ +1.8 pp |
| 2014 | 10.7% | CN¥895.14 Million | CN¥895.14 Million | CN¥- | CN¥8.35 Billion | ▲ +2.2 pp |
| 2013 | 8.5% | CN¥683.72 Million | CN¥683.72 Million | CN¥- | CN¥8.07 Billion | ▲ +3.9 pp |
| 2012 | 4.6% | CN¥367.96 Million | CN¥367.96 Million | CN¥- | CN¥8.05 Billion | ▲ +1.7 pp |
| 2011 | 2.9% | CN¥225.94 Million | CN¥225.94 Million | CN¥- | CN¥7.91 Billion | ▲ +1.2 pp |
| 2010 | 1.7% | CN¥132.82 Million | CN¥132.82 Million | CN¥- | CN¥8.02 Billion | ▼ -9.3 pp |
| 2009 | 10.9% | CN¥116.96 Million | CN¥116.96 Million | CN¥- | CN¥1.07 Billion | ▼ -2.1 pp |
| 2008 | 13.1% | CN¥40.20 Million | CN¥40.20 Million | CN¥- | CN¥307.83 Million | ▼ -14.8 pp |
| 2007 | 27.8% | CN¥40.75 Million | CN¥40.75 Million | CN¥- | CN¥146.44 Million | — |